November 1, 2025Open Access

Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion Burden

View Full Paper

Ask AI

Bookmark

Authors

LWLing WangQingdao University SJShiwei JinShanghai Jiao Tong University MPMengmeng PanShanghai Jiao Tong University

Discussion

Member takes

Implication

Retrospective cohort study found luspatercept improved hemoglobin levels in adults after allogeneic HSCT, suggesting better erythroid recovery and reduced transfusion burden.

Key Points

An 91.8% erythroid response was observed in patients treated with luspatercept after allo-HSCT, indicating improved recovery.
Luspatercept recipients had a greater increase in hemoglobin levels at one week, rising from 55 to 65 g/L.
In a retrospective cohort study, luspatercept reduced the need for RBC transfusion compared to controls, with only 10.2% requiring transfusion.
Findings suggest luspatercept may aid in managing anemia post-HSCT, but prospective trials are needed for confirmation.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69054ffa1a99e50463de69aa https://doi.org/10.21203/rs.3.rs-7900872/v1

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study found luspatercept improved hemoglobin levels in adults after allogeneic HSCT, suggesting better erythroid recovery and reduced transfusion burden.

Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion Burden

Discussion

Member takes

Implication

Key Points

Cite This Study

Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion Burden

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider